Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predictive performance of a vancomycin-aminoglycoside population model

P M Beringer1, A Wong-Beringer, J P Rho

  • 1Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles 90033, USA.

The Annals of Pharmacotherapy
|March 13, 1998
PubMed
Summary

A new model accurately predicts vancomycin serum concentrations by using aminoglycoside pharmacokinetic parameters. This revised model improves vancomycin dosing for patients receiving both drugs, reducing the need for extensive monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria.

Antimicrobial agents and chemotherapy·2022
Same author

Antimicrobial Stewardship Opportunities in Patients with Bacteremia Not Identified by BioFire FilmArray.

Journal of clinical microbiology·2019
Same author

Clinically significant bacteria/pyuria-the author responds.

The American journal of emergency medicine·2017
Same author

Emergency Department Urinary Antibiograms Differ by Specific Patient Group.

Journal of clinical microbiology·2017
Same author

Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2008
Same author

Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.

The Journal of antimicrobial chemotherapy·2002

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Therapeutic Drug Monitoring
  • Antibiotic Stewardship

Background:

  • Accurate prediction of vancomycin serum concentrations is crucial for effective therapeutic drug monitoring.
  • Existing models, like the Wragge-Cooper method, may have limitations in predicting vancomycin levels, especially when used with aminoglycosides.
  • Individualized pharmacokinetic parameter estimation is key to optimizing antibiotic dosing.

Purpose of the Study:

  • To evaluate the Wragge-Cooper method for predicting vancomycin serum concentrations.
  • To develop and validate a revised predictive model incorporating aminoglycoside pharmacokinetic parameters.
  • To assess the model's performance in general medicine and intensive care unit (ICU) populations.

Main Methods:

Related Experiment Videos

  • A retrospective study of 50 adult patients receiving concurrent vancomycin and aminoglycoside therapy.
  • Bayesian analysis to determine individualized pharmacokinetic parameters for both antibiotics.
  • Phase I: Tested Wragge-Cooper model and developed a revised model. Phase II: Validated the revised model against Wragge-Cooper and traditional models.

    • Main Results:

    • The Wragge-Cooper model consistently underpredicted vancomycin concentrations (ME = -5.18, MAE = 6.63).
    • A significant relationship was found between aminoglycoside and vancomycin elimination rates (r = 0.73).
    • The revised model demonstrated significantly improved accuracy (less bias and higher precision) compared to the traditional model.

    Conclusions:

    • The developed revised model accurately predicts vancomycin serum concentrations in both general medicine and ICU settings.
    • This model facilitates individualized vancomycin dosage adjustments in patients receiving concurrent aminoglycoside therapy.
    • The revised model can potentially minimize the frequency of vancomycin serum concentration monitoring.